Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.81 1.18 +1.65%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a

Corcept Therapeutics Incorporated 8-K filed Sep 23, 2026

Period ended Sep 22, 2026 · Filed · accepted 8:15 AM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

Red flags